Peptides / Longevity and mitochondria

Natural peptide · 3 amino acids · 307.3 Da

Glutathione

Approved in JapanNot banned in sport

Glutathione is a natural antioxidant made of three amino acids, used in supplements and approved as a medicine in Japan. Studies in people tested it on blood sugar, nerve protection and safety, and measured how the body absorbs it. PepBank shows 266 results on glutathione from 48 studies in people, and 8 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as GSH, Gamma-L-glutamyl-L-cysteinylglycine, L-glutathione, Reduced glutathione, Tathion

3 amino acids, from first to lastECG

Evidence level: Large trials in people266 of 274 results come from studies in people, including randomized trials.

Results in people

266

97% of 274 results

Results in animals

3% of 274 results

Results in lab cells

under 1% of 274 results

From computer models

0% of 274 results

Overview

Glutathione at a glance

What it is	Natural peptide, 3 amino acids
Approval	Approved in Japan only
In sport	Not listed as banned by WADA
Studies	50 studies with results. 49 of them gave glutathione, with 274 results. 266 in people7 in animals1 in lab cells
Best study in people	Randomized controlled trial with 153 people (2013)
Clinical trials	72 registered: 14 active or planned, 11 with posted results
Community use	Community antioxidant and wellness use

The science

What is glutathione?

Natural gamma-glutamyl tripeptide and antioxidant, used in supplements and nationally approved medicines.

Amino acids in one chain

The history of glutathione

1950
The oldest paper on glutathione in PepBank is from 1950.
2007June
A registered trial of glutathione started (NCT00499122).

Glutathione structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 3 amino acidsFrom the first amino acid to the last

−E1CG

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Glutathione is a natural peptide of 3 amino acids, with no ring, 1 changed amino acid.

Formula

C₁₀H₁₇N₃O₆S

Molecular weight

307.3 g/mol

CAS number

70-18-8

Development

Tathion: Choseido Pharmaceutical (manufacturer). Highest phase: past the trial stage (see status).

Identifiers

PubChem 124886, ChEMBL CHEMBL1543, UNII GAN16C9B8O, DrugBank DB00143

Full sequence, SMILES and InChIKey

Three-letter sequence
H-gamma-Glu-Cys-Gly-OH

InChIKey
RWSXRVCMGQZWBV-WDSKDSINSA-N

SMILES
C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What glutathione studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people266 of 274 results come from studies in people, including randomized trials.

Immune system and inflammation

30 results · 30 in people

In healthy adults, high-dose GSH increased natural killer cell activity compared with placebo. European journal of nutrition, 2015

Top results

In healthy adults, high-dose GSH increased natural killer cell activity compared with placebo. (European journal of nutrition, 2015)
In diabetic patients and healthy controls, glutathione prevented the ICAM-1 increase compared with glucose testing alone. (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1998)
In cystic fibrosis, airway glutathione supplementation showed no evidence of reduced inflammation. (American journal of respiratory and critical care medicine, 2013)

Cells, genes and aging

31 results · 28 in people · 3 animal

In healthy adults, oral glutathione did not significantly change urinary F2-isoprostanes versus placebo. Journal of alternative and complementary medicine, 2011

Top results

In healthy adults, oral glutathione did not significantly change urinary F2-isoprostanes versus placebo. (Journal of alternative and complementary medicine, 2011)
In diabetic individuals, glutathione supplementation decreased a marker of oxidative DNA damage from baseline within three months. (Antioxidants, 2022)
In cystic fibrosis, inhaled glutathione showed no indication of reduced oxidative damage to proteins. (American journal of respiratory and critical care medicine, 2013)

Blood sugar

19 results · 19 in people

In diabetic individuals, glutathione supplementation maintained HbA1c at baseline levels overall. Antioxidants, 2022

Top results

In diabetic individuals, glutathione supplementation maintained HbA1c at baseline levels overall. (Antioxidants, 2022)
In diabetic patients and controls, larger redox ratio increases after glutathione infusion were linked to larger glucose uptake increases. (Metabolism: clinical and experimental, 1998)
In obese subjects with and without diabetes, insulin sensitivity increased from baseline in the glutathione group. (Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 2021)

Skin, hair and wounds

17 results · 17 in people

In patients with ovarian cancer, glutathione improved the hair loss score compared with control. Annals of oncology, 1997

Top results

In patients with ovarian cancer, glutathione improved the hair loss score compared with control. (Annals of oncology, 1997)
In healthy medical students, glutathione reduced skin melanin on the right face more than placebo. (The Journal of dermatological treatment, 2012)
In healthy women, topical GSSG increased skin moisture compared with placebo. (Clinical, cosmetic and investigational dermatology, 2014)

Daily life and fitness

16 results · 16 in people

In Parkinson's disease, glutathione did not significantly change disease rating scores compared with placebo. Movement disorders, 2009

Top results

In Parkinson's disease, glutathione did not significantly change disease rating scores compared with placebo. (Movement disorders, 2009)
In patients with ovarian cancer, glutathione improved ability to do housekeeping compared with control. (Annals of oncology, 1997)
In peripheral artery disease, glutathione increased pain-free walking distance compared with pretreatment values. (Mayo Clinic proceedings, 2002)

Brain and nerves

14 results · 14 in people

In patients receiving paclitaxel and carboplatin, sensory nerve toxicity did not differ significantly between GSH and placebo. Cancer, 2014

Top results

In patients receiving paclitaxel and carboplatin, sensory nerve toxicity did not differ significantly between GSH and placebo. (Cancer, 2014)
In patients with advanced gastric cancer, nerve conduction decreased significantly with placebo but not glutathione. (Journal of clinical oncology, 1995)
In colorectal cancer receiving oxaliplatin, neurotoxicity affected nine of 21 glutathione recipients versus 15 of 19 placebo recipients after the eighth cycle. (Journal of clinical oncology, 2002)

All 50 glutathione studies by area Open the Scientific page

Key glutathione studies

Studies in people come first, then studies in animals and in the lab.

People
Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial
Griese et al. 2013 · American journal of respiratory and critical care medicine · 153 people · cited by 67
12 results
People
Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis
Calabrese et al. 2015 · Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 105 people · cited by 22
4 results
People
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study
Arjinpathana et al. 2012 · The Journal of dermatological treatment · 60 people · cited by 62
5 results
People
Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers
Allen et al. 2011 · Journal of alternative and complementary medicine (New York, N.Y.) · 39 people · cited by 110
5 results
People
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie et al. 2015 · European journal of nutrition · cited by 80
11 results

All 50 Glutathione studies

Glutathione clinical trials

ClinicalTrials.gov lists 72 trials of glutathione. 14 are active or planned, and 11 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Phase 3completed195 people

A Study of Glutathione in Children With Autism Spectrum Disorder

Phase 4terminated6 planned

Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation

Phase 3completed157 people

All 17 Glutathione trials

Status and safety

Is glutathione approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in Japan only. No FDA approval and no central EU authorisation (EMA). Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Glutathione side effects and safety

PepBank has 34 safety results from studies of glutathione. 34 of them come from studies in people.

Safety results from studies (34)

In chemotherapy patients, apparent toxicities did not differ significantly between GSH and placebo. (Cancer, 2014)
In cystic fibrosis, adverse events occurred at similar rates with glutathione and placebo. (American journal of respiratory and critical care medicine, 2013)
In patients with ovarian cancer, glutathione improved the hair loss score compared with control. (Annals of oncology, 1997)
In cystic fibrosis, all patients tolerated inhaled GSH well. (Journal of cystic fibrosis, 2015)
In healthy medical students, both glutathione and placebo were very well tolerated. (The Journal of dermatological treatment, 2012)
In patients with advanced gastric cancer, neuropathy occurred less often with glutathione than placebo at week 9. (Journal of clinical oncology, 1995)
In healthy women, topical GSSG application produced no marked adverse effects. (Clinical, cosmetic and investigational dermatology, 2014)
In melasma patients, redness did not differ significantly between cocktails with and without glutathione. (Journal of cosmetic dermatology, 2019)
In Parkinson's disease, no participants withdrew because of adverse events in either the glutathione or placebo group. (Movement disorders, 2009)
In people with head and neck or lung cancer on cisplatin, hemoglobin was higher with glutathione than with intensive hydration. (Wiener klinische Wochenschrift, 2000)
In patients with mild asthma, inhaled glutathione reduced lung function more than placebo. (American journal of respiratory and critical care medicine, 1997)
In Parkinson's disease, one participant receiving high-dose GSH developed heart muscle disease. (Journal of Parkinson's disease, 2017)
In healthy women, the GSH and GSSG study reported no serious adverse effects. (Clinical, cosmetic and investigational dermatology, 2017)
In cystic fibrosis, lung function transiently decreased after glutathione inhalation. (American journal of respiratory and critical care medicine, 2004)
In patients receiving chemotherapy, glutathione reduced bone marrow suppression compared with the standard regimen without glutathione. (Tumori, 1987)
In patients with ovarian cancer, glutathione improved the breathlessness score compared with control. (Annals of oncology, 1997)
In patients with advanced gastric cancer, nerve conduction decreased significantly with placebo but not glutathione. (Journal of clinical oncology, 1995)
In patients with advanced gastric cancer, glutathione reduced transfusion requirements compared with placebo. (Journal of clinical oncology, 1995)
In patients with advanced gastric cancer, neurotoxicity occurred less often with glutathione than placebo after week 15. (Journal of clinical oncology, 1995)
In melasma patients, swelling did not differ significantly between cocktails with and without glutathione. (Journal of cosmetic dermatology, 2019)
In melasma patients, bruising did not differ significantly between cocktails with and without glutathione. (Journal of cosmetic dermatology, 2019)
In Parkinson's disease, reported adverse events were similar with glutathione and placebo. (Movement disorders, 2009)
In people with head and neck or lung cancer on cisplatin, white blood cell count was higher with glutathione than with intensive hydration. (Wiener klinische Wochenschrift, 2000)
In people with head and neck or lung cancer on cisplatin, platelet count was higher with glutathione than with intensive hydration. (Wiener klinische Wochenschrift, 2000)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
646 mg every 12 hours	Human	human	inhalation via eFlow nebulizer	6 months	Randomized trial in people · n = 153	Griese 2013
500 mg/day in two divided doses	Human	human	oral	4 weeks	Randomized trial in people · n = 60	Arjinpathana 2012
500 mg twice daily	Human	human	oral	4 weeks	Randomized trial in people · n = 39	Allen 2011
1,000 mg/day	Human	human	oral	3 months	Randomized trial in people	Richie 2015
1.5 g/m(2)	Human	human	Not reported	Not reported	Randomized trial in people · n = 185	Leal 2014
500 mg daily	Human	human	oral	six months	Randomized trial in people · n = 125	Kalamkar 2022
1,500 mg/m(2) before oxaliplatin	Human	human	infusion over 15 minutes	Not reported	Randomized trial in people · n = 52	Cascinu 2002
1.5 g/m2 before CDDP and 600 mg on days 2 to 5	Human	human	infusion and intramuscular injection	9 weeks	Randomized trial in people · n = 50	Cascinu 1995
600 mg each day	Human	human	intramuscular	12 weeks	Randomized trial in people · n = 32	Chiò 1998
2% (weight/weight [w/w]) lotion twice daily	Human	human	topical	10 weeks	Randomized trial in people · n = 30	Watanabe 2014
2%	Human	human	mesotherapy	six sessions at 2-week intervals	Randomized trial in people · n = 30	Iraji 2019
1500 mg/m before oxaliplatin infusion	Human	human	Not reported	Not reported	Randomized trial in people · n = 27	Milla 2009
1,400 mg three times a week	Human	human	intravenous	4 weeks	Randomized trial in people · n = 21	Hauser 2009
600 mg every other day	Human	human	intramuscular	2 months	Randomized trial in people · n = 20	Lenzi 1993
1.35 g x m2 x min(-1)	Human	human	intravenous	1 hour	Randomized trial in people · n = 20	De 1998
5 g immediately before cisplatin	Human	human	Not reported	Not reported	Randomized trial in people · n = 20	Schmidinger 2000
5 g	Human	human	Not reported	Not reported	Randomized trial in people · n = 20	Schmidinger 2000
1000 mg per day	Human	human	oral	3 weeks	Randomized trial in people · n = 20	Søndergård 2021
600 mg	Human	human	nebulized	25 min	Randomized trial in people · n = 8	Marrades 1997
250 or 1,000 mg/day	Human	human	oral	1, 3 and 6 months	Randomized trial in people	Richie 2015
250 mg/day	Human	human	oral	6 months	Randomized trial in people	Richie 2015
200 mg thrice daily	Human	human	intranasal	three months	Randomized trial in people	Mischley 2017
100 mg thrice daily	Human	human	intranasal	three months	Randomized trial in people	Mischley 2017
250 mg/d	Human	human	oral	12 weeks	Randomized trial in people	Weschawalit 2017
300 mg/day	Human	human	oral	4 months	Trial in people without random groups · n = 29	Honda 2017
1 g/m2 bolus + 1 g/m2 in 2 h	Human	human	intravenous	2 h	Trial in people without random groups · n = 20	Cerielo 1997
300 or 450 mg thrice daily	Human	human	inhalation	14 days	Trial in people without random groups · n = 17	Griese 2004
1500 mg/m2	Human	human	Not reported	maximum of five consecutive courses	Trial in people without random groups · n = 16	Oriana 1987
200 mg	Human	human	intranasal	Not reported	Trial in people without random groups · n = 15	Mischley 2016
500 and 1000 mg per day	Human	human	oral	1 month	Trial in people without random groups · n = 12	Sinha 2018
600 mg/day	Human	human	IM	2 months	Trial in people without random groups · n = 11	Lenzi 1992
15 mg/min	Human	human	infusion	Not reported	Trial in people without random groups · n = 10	Paolisso 1992
2 g m-2	Human	human	intravenous	Not reported	Trial in people without random groups · n = 10	Aebi 1991
10 mg/min	Human	human	infusion	Not reported	Trial in people without random groups · n = 10	Paolisso 1992
600 mg twice daily	Human	human	intravenous	30 days	Trial in people without random groups · n = 9	Sechi 1996
600 mg bolus followed by 5 mg/min infusion	Human	human	intravenous	Not reported	Trial in people without random groups · n = 8	Marfella 2000
1 g/d	Human	human	Not reported	2 weeks	Trial in people without random groups · n = 8	Aoi 2015
0.15 mmol.kg-1	Human	human	oral	270 min	Trial in people without random groups · n = 7	Witschi 1992
66-148 mg/kg/day in divided doses	Human	human	oral and inhaled	5.5 months	Observational study · n = 13	Visca 2008
2 g	Human	human	oral or intravenous	Not reported	Reports of single patients · n = 2	Horowitz 2020

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The source reports this use pattern. It does not establish safety or efficacy.

Reported routines and cautions

What people use it for

Community antioxidant and wellness useS1

Reported regimens

Regimens that community sources report for Glutathione. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community antioxidant and wellness use	intravenous	600 to 1200 mg per dose	1-2 times weekly	4-6 weeks (initial), then biweekly maintenance	single secondary source. The wiki links to seller pages. The checked pages do not disclose an affiliate relationship.	S1
Japanese label adult regimenOfficial label dosing of an approved product	intramuscular or intravenous injection	100 to 200 mg per dose	once daily	Not stated	single source	S2

Community sources

S1Glutathione community protocols (opens in a new tab)www.peptideprotocolwiki.com
S2PMDA Tathion injection label (opens in a new tab)www.pmda.go.jp

Gaps

The community regimen comes from one secondary wiki source. The label regimen describes Japanese Tathion only. The sources do not establish product or dose equivalence. The community source does not define biweekly. The checked pages do not establish an affiliate relationship.

Questions and more

Ask a question about glutathione

The answer links to every study it uses.

What does the evidence say about glutathione?Is glutathione tested in people?Compare with NMN (nicotinamide mononucleotide)Compare with Elamipretide (SS-31)

Sources

Database: PepBank data for glutathione (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about glutathione

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Glutathione

Approved in JapanNot banned in sport

Also known as GSH, Gamma-L-glutamyl-L-cysteinylglycine, L-glutathione, Reduced glutathione, Tathion

What it is

Natural peptide, 3 amino acids

Approval

Approved in Japan only

In sport

Not listed as banned by WADA

Studies

50 studies with results. 49 of them gave glutathione, with 274 results.
266 in people7 in animals1 in lab cells

Best study in people

Randomized controlled trial with 153 people (2013)

Clinical trials

72 registered: 14 active or planned, 11 with posted results

Community use

Community antioxidant and wellness use

Dose as reported

Class

Species

Route

Duration

Design

Source

646 mg every 12 hours

Human

human

inhalation via eFlow nebulizer

6 months

Randomized trial in people · n = 153

Griese 2013

500 mg/day in two divided doses

Human

human

oral

4 weeks

Randomized trial in people · n = 60

Arjinpathana 2012

500 mg twice daily

Human

human

oral

4 weeks

Randomized trial in people · n = 39

Allen 2011

1,000 mg/day

Human

human

oral

3 months

Randomized trial in people

Richie 2015

1.5 g/m(2)

Human

human

Not reported

Randomized trial in people · n = 185

Leal 2014

500 mg daily

Human

human

oral

six months

Randomized trial in people · n = 125

Kalamkar 2022

1,500 mg/m(2) before oxaliplatin

Human

human

infusion over 15 minutes

Not reported

Randomized trial in people · n = 52

Cascinu 2002

1.5 g/m2 before CDDP and 600 mg on days 2 to 5

Human

human

infusion and intramuscular injection

9 weeks

Randomized trial in people · n = 50

Cascinu 1995

600 mg each day

Human

human

intramuscular

12 weeks

Randomized trial in people · n = 32

Chiò 1998

2% (weight/weight [w/w]) lotion twice daily

Human

human

topical

10 weeks

Randomized trial in people · n = 30

Watanabe 2014

Human

human

mesotherapy

six sessions at 2-week intervals

Randomized trial in people · n = 30

Iraji 2019

1500 mg/m before oxaliplatin infusion

Human

human

Not reported

Randomized trial in people · n = 27

Milla 2009

1,400 mg three times a week

Human

human

intravenous

4 weeks

Randomized trial in people · n = 21

Hauser 2009

600 mg every other day

Human

human

intramuscular

2 months

Randomized trial in people · n = 20

Lenzi 1993

1.35 g x m2 x min(-1)

Human

human

intravenous

1 hour

Randomized trial in people · n = 20

De 1998

5 g immediately before cisplatin

Human

human

Not reported

Randomized trial in people · n = 20

Schmidinger 2000

5 g

Human

human

Not reported

Randomized trial in people · n = 20

Schmidinger 2000

1000 mg per day

Human

human

oral

3 weeks

Randomized trial in people · n = 20

Søndergård 2021

600 mg

Human

human

nebulized

25 min

Randomized trial in people · n = 8

Marrades 1997

250 or 1,000 mg/day

Human

human

oral

1, 3 and 6 months

Randomized trial in people

Richie 2015

250 mg/day

Human

human

oral

6 months

Randomized trial in people

Richie 2015

200 mg thrice daily

Human

human

intranasal

three months

Randomized trial in people

Mischley 2017

100 mg thrice daily

Human

human

intranasal

three months

Randomized trial in people

Mischley 2017

250 mg/d

Human

human

oral

12 weeks

Randomized trial in people

Weschawalit 2017

300 mg/day

Human

human

oral

4 months

Trial in people without random groups · n = 29

Honda 2017

1 g/m2 bolus + 1 g/m2 in 2 h

Human

human

intravenous

2 h

Trial in people without random groups · n = 20

Cerielo 1997

300 or 450 mg thrice daily

Human

human

inhalation

14 days

Trial in people without random groups · n = 17

Griese 2004

1500 mg/m2

Human

human

Not reported

maximum of five consecutive courses

Trial in people without random groups · n = 16

Oriana 1987

200 mg

Human

human

intranasal

Not reported

Trial in people without random groups · n = 15

Mischley 2016

500 and 1000 mg per day

Human

human

oral

1 month

Trial in people without random groups · n = 12

Sinha 2018

600 mg/day

Human

human

2 months

Trial in people without random groups · n = 11

Lenzi 1992

15 mg/min

Human

human

infusion

Not reported

Trial in people without random groups · n = 10

Paolisso 1992

2 g m-2

Human

human

intravenous

Not reported

Trial in people without random groups · n = 10

Aebi 1991

10 mg/min

Human

human

infusion

Not reported

Trial in people without random groups · n = 10

Paolisso 1992

600 mg twice daily

Human

human

intravenous

30 days

Trial in people without random groups · n = 9

Sechi 1996

600 mg bolus followed by 5 mg/min infusion

Human

human

intravenous

Not reported

Trial in people without random groups · n = 8

Marfella 2000

1 g/d

Human

human

Not reported

2 weeks

Trial in people without random groups · n = 8

Aoi 2015

0.15 mmol.kg-1

Human

human

oral

270 min

Trial in people without random groups · n = 7

Witschi 1992

66-148 mg/kg/day in divided doses

Human

human

oral and inhaled

5.5 months

Observational study · n = 13

Visca 2008

2 g

Human

human

oral or intravenous

Not reported

Reports of single patients · n = 2

Horowitz 2020

Context

Route

Amount

How often

How long

Agreement

Sources

Community antioxidant and wellness use

intravenous

600 to 1200 mg per dose

1-2 times weekly

4-6 weeks (initial), then biweekly maintenance

single secondary source. The wiki links to seller pages. The checked pages do not disclose an affiliate relationship.

Japanese label adult regimenOfficial label dosing of an approved product

intramuscular or intravenous injection

100 to 200 mg per dose

once daily

Not stated

single source

Glutathione

Glutathione at a glance

What is glutathione?

The history of glutathione

Glutathione structure and chemistry

What glutathione studies show

Immune system and inflammation

Cells, genes and aging

Blood sugar

Skin, hair and wounds

Daily life and fitness

Brain and nerves

Key glutathione studies

Glutathione clinical trials

Is glutathione approved?

Glutathione side effects and safety

How people use it

What people use it for

Reported regimens

Community sources

Ask a question about glutathione

Related peptides

Sources

Glutathione

Glutathione at a glance

What is glutathione?

The history of glutathione

Glutathione structure and chemistry

What glutathione studies show

Immune system and inflammation

Cells, genes and aging

Blood sugar

Skin, hair and wounds

Daily life and fitness

Brain and nerves

Key glutathione studies

Glutathione clinical trials

Is glutathione approved?

Glutathione side effects and safety

How people use it

What people use it for

Reported regimens

Community sources

Ask a question about glutathione

Related peptides

Sources